Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
4,142 JPY | +0.10% | -2.13% | +2.17% |
Sales 2024 | 4,264B 27.08B | Sales 2025 * | 4,269B 27.11B | Capitalization | 6,499B 41.27B |
---|---|---|---|---|---|
Net income 2024 | 144B 915M | Net income 2025 * | 103B 655M | EV / Sales 2024 | 2.57 x |
Net Debt 2024 | 4,386B 27.86B | Net Debt 2025 * | 4,189B 26.6B | EV / Sales 2025 * | 2.5 x |
P/E ratio 2024 |
45.4
x | P/E ratio 2025 * |
64.1
x | Employees | 49,095 |
Yield 2024 |
4.49% | Yield 2025 * |
4.69% | Free-Float | 99.12% |
Latest transcript on Takeda Pharmaceutical Company Limited
1 day | +0.10% | ||
1 week | -2.13% | ||
Current month | -0.74% | ||
1 month | -1.50% | ||
3 months | -3.40% | ||
6 months | +3.06% | ||
Current year | +2.17% |
Managers | Title | Age | Since |
---|---|---|---|
Christophe Weber
CEO | Chief Executive Officer | 57 | 14-03-31 |
Gabriele Ricci
CTO | Chief Tech/Sci/R&D Officer | 45 | 22-01-31 |
Mwana Lugogo
CMP | Compliance Officer | 54 | 11-12-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Director/Board Member | 71 | 16-05-31 | |
Ian Clark
BRD | Director/Board Member | 62 | 18-12-31 |
Steven Gillis
BRD | Director/Board Member | 71 | 18-12-31 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
24.44% | 14 M€ | +9.43% | ||
3.80% | 1,476 M€ | +21.94% | ||
3.43% | 240 M€ | +19.42% | ||
3.26% | 58 M€ | +22.62% |
Date | Price | Change | Volume |
---|---|---|---|
24-06-14 | 4,142 | +0.10% | 4,772,700 |
24-06-13 | 4,138 | -0.65% | 2,704,600 |
24-06-12 | 4,165 | -1.28% | 3,282,500 |
24-06-11 | 4,219 | -0.52% | 2,688,400 |
24-06-10 | 4,241 | +0.21% | 2,236,500 |
Delayed Quote Japan Exchange, June 14, 2024 at 02:00 am EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+2.17% | 41.3B | |
+50.70% | 791B | |
+41.96% | 630B | |
-7.15% | 350B | |
+18.77% | 328B | |
+8.79% | 298B | |
+18.02% | 246B | |
+1.27% | 225B | |
+11.95% | 218B | |
+3.68% | 160B |
- Stock Market
- Equities
- 4502 Stock